{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:05:06Z","timestamp":1759334706456,"version":"build-2065373602"},"reference-count":42,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100012021","name":"Iran University of Medical Sciences","doi-asserted-by":"publisher","award":["16396"],"award-info":[{"award-number":["16396"]}],"id":[{"id":"10.13039\/100012021","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Medical Research"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.arcmed.2022.09.004","type":"journal-article","created":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T22:13:41Z","timestamp":1665180821000},"page":"666-672","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-Term Follow-Up of Thalassemia Major Patients with Hepatitis C Virus Treated with Sofosbuvir and Daclatasvir: A Cohort Study"],"prefix":"10.1016","volume":"53","author":[{"given":"Fahimeh","family":"Safarnezhad Tameshkel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1364-5743","authenticated-orcid":false,"given":"Mohammad Hadi","family":"Karbalaie Niya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bahareh","family":"Amirkalali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nima","family":"Motamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamshid","family":"Vafaeimanesh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mansooreh","family":"Maadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masodreza","family":"Sohrabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir Hossein","family":"Faraji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoodreza","family":"Khoonsari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hossein","family":"Ajdarkosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehdi","family":"Nikkhah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elham","family":"Sobh Rakhashankhah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farhad","family":"Zamani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.arcmed.2022.09.004_bib0001","doi-asserted-by":"crossref","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","article-title":"Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review","volume":"5","author":"Degenhardt","year":"2017","journal-title":"Lancet Glob Heal"},{"key":"10.1016\/j.arcmed.2022.09.004_bib0002","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","author":"Blach","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.arcmed.2022.09.004_bib0003","unstructured":"World Health Organization. Global hepatitis report 2017: https:\/\/www.who.int\/publications-detail-redirect\/global-hepatitis-report-2017. 19 April 2017 Meeting report. (Accessed January 14, 2022)."},{"key":"10.1016\/j.arcmed.2022.09.004_bib0004","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1136\/jcp.43.8.638","article-title":"Antibody to hepatitis C virus in multiply transfused patients with thalassaemia major","volume":"43","author":"Wonke","year":"1990","journal-title":"J clin Pathol"},{"key":"10.1016\/j.arcmed.2022.09.004_bib0005","article-title":"Epidemiology of transfusion transmitted infection among patients with \u03b2-thalassaemia major in Pakistan","volume":"2016","author":"Ahmed Kiani","year":"2016","journal-title":"J Blood Transfus"},{"issue":"Suppl 1","key":"10.1016\/j.arcmed.2022.09.004_bib0006","first-page":"703","article-title":"WHO guidelines on testing for hepatitis B and C\u2013meeting targets for testing","volume":"17","author":"Hellard","year":"2017","journal-title":"Springer"},{"issue":"2","key":"10.1016\/j.arcmed.2022.09.004_bib0007","article-title":"Distribution of Hepatitis C virus genotypes in Rasht, capital City of Guilan province","volume":"18","author":"Naghipour-Khalkhaliani","year":"2018","journal-title":"Northern Part of Iran. Hepat Mon"},{"key":"10.1016\/j.arcmed.2022.09.004_bib0008","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4103\/2008-7802.164832","article-title":"Trend in prevalence of hepatitis C virus infection among \u03b2-thalassemia major patients: 10 years of experience in Iran","volume":"6","author":"Jafroodi","year":"2015","journal-title":"Int J Prev Med"},{"key":"10.1016\/j.arcmed.2022.09.004_bib0009","first-page":"45","article-title":"Frequency of thalassemia in Iran and Khorasan Razavi","volume":"1","author":"Khodaei","year":"2013","journal-title":"Int J Pediatr"},{"key":"10.1016\/j.arcmed.2022.09.004_bib0010","doi-asserted-by":"crossref","first-page":"e10236","DOI":"10.5812\/hepatmon.10236","article-title":"Cost-effectiveness analysis of adding low dose ribavirin to peginterferon alfa-2a for treatment of chronic hepatitis C infected thalassemia major patients in iran","volume":"13","author":"Mehrazmay","year":"2013","journal-title":"Hepat Mon"},{"key":"10.1016\/j.arcmed.2022.09.004_bib0011","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1007\/s00705-016-2862-3","article-title":"Prevalence of occult hepatitis C virus infection in Iranian patients with beta thalassemia major","volume":"161","author":"Bastani","year":"2016","journal-title":"Arch Virol"},{"key":"10.1016\/j.arcmed.2022.09.004_bib0012","doi-asserted-by":"crossref","first-page":"S127","DOI":"10.1016\/S1995-7645(14)60218-2","article-title":"Prevalence of hepatitis C virus infection among thalassemia patients: a perspective from a multi-ethnic population of Pakistan","volume":"7","author":"Din","year":"2014","journal-title":"Asian Pac J Trop Med"},{"key":"10.1016\/j.arcmed.2022.09.004_bib0013","doi-asserted-by":"crossref","first-page":"372","DOI":"10.5812\/hepatmon.6592","article-title":"Low dose ribavirin for treatment of hepatitis C virus infected thalassemia major patients; new indications for combination therapy","volume":"12","author":"Tabatabaei","year":"2012","journal-title":"Hepat Mon"},{"key":"10.1016\/j.arcmed.2022.09.004_bib0014","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/hep.31060","article-title":"Hepatitis C guidance 2019 update: American Association for the Study of Liver Diseases\u2013Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection","volume":"71","author":"Ghany","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.arcmed.2022.09.004_bib0015","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL recommendations on treatment of hepatitis C 2018","volume":"69","author":"EAfTSoT","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.arcmed.2022.09.004_bib0016","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/apt.13633","article-title":"Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis","volume":"43","author":"Majumdar","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.arcmed.2022.09.004_bib0017","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2147\/HMER.S55864","article-title":"Interferon-free combination therapies for the treatment of hepatitis C: current insights","volume":"7","author":"Holmes","year":"2015","journal-title":"Hepat Med"},{"key":"10.1016\/j.arcmed.2022.09.004_bib0018","doi-asserted-by":"crossref","first-page":"329","DOI":"10.7326\/0003-4819-158-5-201303050-00005","article-title":"Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies","volume":"158","author":"Morgan","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.arcmed.2022.09.004_bib0019","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1093\/cid\/cir076","article-title":"Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more","volume":"52","author":"Pearlman","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.arcmed.2022.09.004_bib0020","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.jhep.2016.01.029","article-title":"Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis","volume":"64","author":"Foster","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.arcmed.2022.09.004_bib0021","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jhep.2016.06.019","article-title":"Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis","volume":"65","author":"Cheung","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.arcmed.2022.09.004_bib0022","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1002\/hep.28632","article-title":"Changes in patient backgrounds may increase the incidence of HCC after SVR in the era of IFN-free therapy for HCV","volume":"64","author":"Toyoda","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.arcmed.2022.09.004_bib0023","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/hep.28535","article-title":"Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection","volume":"64","author":"El-Serag","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.arcmed.2022.09.004_bib0024","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/apt.14197","article-title":"Randomised clinical trial: sofosbuvir and ledipasvir in patients with transfusion-dependent thalassaemia and HCV genotype 1 or 4 infection","volume":"46","author":"Mangia","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.arcmed.2022.09.004_bib0025","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1002\/hep.29139","article-title":"Elbasvir\/grazoprevir for patients with hepatitis C virus infection and inherited blood disorders: a phase III study","volume":"66","author":"H\u00e9zode","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.arcmed.2022.09.004_bib0026","doi-asserted-by":"crossref","first-page":"e37089","DOI":"10.5812\/hepatmon.37089","article-title":"Next steps toward eradication of hepatitis C in the era of direct acting antivirals","volume":"16","author":"Hesamizadeh","year":"2016","journal-title":"Hepat Mon"},{"key":"10.1016\/j.arcmed.2022.09.004_bib0027","doi-asserted-by":"crossref","first-page":"224","DOI":"10.4103\/ijmm.IJMM_18_90","article-title":"The effectiveness of sofosbuvir and daclatasvir in the treatment of hepatitis C in thalassaemia major patients and their effect on haematological factors","volume":"36","author":"Zamani","year":"2018","journal-title":"Indian j Med Microbiol"},{"key":"10.1016\/j.arcmed.2022.09.004_bib0028","first-page":"216","article-title":"Polymorphism of IL-28B gene (rs12979860) in HCV genotype 1patients treated by pegylated interferon and ribavirin","volume":"11","author":"Tameshkel","year":"2016","journal-title":"Iranian J Pathol"},{"key":"10.1016\/j.arcmed.2022.09.004_bib0029","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.micpath.2017.01.060","article-title":"Prevalence of resistant associated variants (RAVs) in the na\u00efve HCV patient candidate for direct acting antiviral (DAA) therapy","volume":"105","author":"Niya","year":"2017","journal-title":"Microb Pathog"},{"key":"10.1016\/j.arcmed.2022.09.004_bib0030","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1136\/gutjnl-2016-312444","article-title":"Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort","volume":"65","author":"Welzel","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.arcmed.2022.09.004_bib0031","unstructured":"US Department of Health and Human Services. National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.0.[November 2014]. Jan 2015."},{"key":"10.1016\/j.arcmed.2022.09.004_bib0032","doi-asserted-by":"crossref","first-page":"e23564","DOI":"10.5812\/hepatmon.23564","article-title":"Efficacy of prolonged treatment with pegylated interferon (Peg-IFN) and ribavirin in thalassemic patients with hepatitis C who relapsed after previous peg-IFN-based therapy","volume":"15","author":"Sandoughdaran","year":"2015","journal-title":"Hepat mon"},{"key":"10.1016\/j.arcmed.2022.09.004_bib0033","first-page":"926","article-title":"Treatment of chronic hepatitis C in thalassemia major patients","volume":"67","author":"Sajjad","year":"2017","journal-title":"J Pak Med Assoc"},{"key":"10.1016\/j.arcmed.2022.09.004_bib0034","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for HCV infection","volume":"370","author":"Sulkowski","year":"2014","journal-title":"The New England J Med"},{"key":"10.1016\/j.arcmed.2022.09.004_bib0035","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis","volume":"370","author":"Kowdley","year":"2014","journal-title":"New England J Med"},{"key":"10.1016\/j.arcmed.2022.09.004_bib0036","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2147\/TCRM.S134818","article-title":"Efficacy and safety outcomes of sofosbuvir-based treatment regimens for hepatitis C virus-infected patients with or without cirrhosis from phase III clinical trials","volume":"13","author":"Yang","year":"2017","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.arcmed.2022.09.004_bib0037","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s12098-018-2752-7","article-title":"Treatment of chronic hepatitis C infection with direct acting antivirals in adolescents with thalassemia major","volume":"86","author":"Nagral","year":"2019","journal-title":"Indian Pediatr"},{"key":"10.1016\/j.arcmed.2022.09.004_bib0039","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.dld.2018.01.108","article-title":"Is stiffness reliable for the detection of liver fibrosis in HCV patients treated with direct acting antiviral drugs (DAAs)? A prospective cohort study","volume":"50","author":"Gaia","year":"2018","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.arcmed.2022.09.004_bib0040","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.2215\/CJN.02510317","article-title":"Effect of sofosbuvir-based hepatitis C virus therapy on kidney function in patients with CKD","volume":"12","author":"Sise","year":"2017","journal-title":"Clin j Am Soc Nephrol"},{"key":"10.1016\/j.arcmed.2022.09.004_bib0041","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1111\/liv.13863","article-title":"Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease","volume":"38","author":"Kumar","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.arcmed.2022.09.004_bib0042","first-page":"1","article-title":"Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study","volume":"8","author":"Liu","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.arcmed.2022.09.004_bib0043","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/liv.13659","article-title":"The impact of treatment of hepatitis C with DAA s on the occurrence of HCC","volume":"38","author":"Roche","year":"2018","journal-title":"Liver Int"}],"container-title":["Archives of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440922001187?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440922001187?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T19:51:35Z","timestamp":1759261895000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0188440922001187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0188440922001187"],"URL":"https:\/\/doi.org\/10.1016\/j.arcmed.2022.09.004","relation":{},"ISSN":["0188-4409"],"issn-type":[{"type":"print","value":"0188-4409"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-Term Follow-Up of Thalassemia Major Patients with Hepatitis C Virus Treated with Sofosbuvir and Daclatasvir: A Cohort Study","name":"articletitle","label":"Article Title"},{"value":"Archives of Medical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arcmed.2022.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Instituto Mexicano del Seguro Social (IMSS). Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}